BML 4.93 Increased By ▲ 0.08 (1.65%)
BOP 12.94 Decreased By ▼ -0.09 (-0.69%)
CNERGY 7.14 Increased By ▲ 0.07 (0.99%)
CPHL 84.96 Increased By ▲ 0.95 (1.13%)
DCL 13.80 Increased By ▲ 0.50 (3.76%)
DGKC 173.11 Increased By ▲ 1.18 (0.69%)
FCCL 46.20 Increased By ▲ 0.13 (0.28%)
FFL 15.89 Increased By ▲ 0.19 (1.21%)
GCIL 26.96 Increased By ▲ 1.04 (4.01%)
HUBC 150.00 Increased By ▲ 4.44 (3.05%)
KEL 5.28 Increased By ▲ 0.03 (0.57%)
KOSM 6.42 Increased By ▲ 0.01 (0.16%)
LOTCHEM 20.80 Increased By ▲ 0.28 (1.36%)
MLCF 85.63 Increased By ▲ 0.76 (0.9%)
NBP 126.10 Increased By ▲ 1.33 (1.07%)
PAEL 41.76 Increased By ▲ 0.04 (0.1%)
PIAHCLA 22.19 Decreased By ▼ -0.14 (-0.63%)
PIBTL 10.22 Increased By ▲ 0.53 (5.47%)
POWER 13.97 Increased By ▲ 0.09 (0.65%)
PPL 165.00 Increased By ▲ 1.53 (0.94%)
PREMA 42.10 Decreased By ▼ -0.34 (-0.8%)
PRL 33.00 Increased By ▲ 0.18 (0.55%)
PTC 22.80 Increased By ▲ 0.89 (4.06%)
SNGP 118.29 Increased By ▲ 1.30 (1.11%)
SSGC 45.25 Decreased By ▼ -0.27 (-0.59%)
TELE 8.00 Increased By ▲ 0.09 (1.14%)
TPLP 10.18 Decreased By ▼ -0.07 (-0.68%)
TREET 24.12 Increased By ▲ 0.73 (3.12%)
TRG 56.90 Increased By ▲ 0.50 (0.89%)
WTL 1.53 No Change ▼ 0.00 (0%)
BR100 14,141 Increased By 276.6 (2%)
BR30 40,136 Increased By 636.7 (1.61%)
KSE100 138,666 Increased By 2285.5 (1.68%)
KSE30 42,353 Increased By 806.9 (1.94%)

LONDON: Britain will start rolling out Pfizer's COVID-19 pill to vulnerable people next month, the health ministry said on Friday, targeting the treatment at people with compromised immune systems for whom the vaccine can be less effective.

The health ministry said that Pfizer's antiviral treatment Paxlovid, a combination of Pfizer's pill with an older antiviral ritonavir, will be made available to thousands of people from Feb. 10.

"It is fantastic news that this new treatment, the latest cutting-edge drug that the NHS is rolling out through new COVID-19 medicine delivery units, will now be available to help those at highest risk of COVID-19," National Health Service medical director Stephen Powis said.

Britain approves Pfizer's antiviral COVID-19 pill

"Trials have shown it can reduce hospitalisation and risk of death by 88%, meaning we'll be in the best position to save thousands of lives."

Britain has ordered 2.75 million courses of Paxlovid, and the government said that it would set out further details on access to the treatment soon but that people who are immunocompromised, cancer patients or those with Down's Syndrome could be able to access it directly.

Merck's COVID-19 pill active against Omicron in lab studies

It is the second antiviral being rolled out in Britain after molnupiravir, a pill made by Merck and Ridgeback Biotherapeutics which is being deployed to patients through the Panoramic trial.

Comments

Comments are closed.